Register entry
- Registered sites
- 0
- Active NDC listings
- 13
- Live patents
- 37
- Countries
- 0
Catalogue
Drug listings by form and route
1313 active NDC listings: 13 human prescription drug. By marketing category: NDA 13.
| Dosage form | NDCs |
|---|---|
| suspension, extended release | 6 |
| tablet, extended release | 4 |
| tablet, chewable, extended release | 3 |
| Route | NDCs |
|---|---|
| oral | 13 |
| Labeller name on the listing | NDCs |
|---|---|
| nextwave pharmaceuticals, inc | 13 |
Exclusivity
Patents and exclusivities
37| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8202537 | QUILLICHEW ERmethylphenidate hydrochloride | product | Mar 2027 |
| 8062667 | QUILLIVANT XRmethylphenidate hydrochloride | product | Mar 2029 |
| 8287903 | QUILLICHEW ER, QUILLIVANT XRmethylphenidate hydrochloride | product | Feb 2031 |
| 8465765 | QUILLIVANT XRmethylphenidate hydrochloride | product | Feb 2031 |
| 8563033 | QUILLIVANT XRmethylphenidate hydrochloride | product | Feb 2031 |
| 8778390 | QUILLIVANT XRmethylphenidate hydrochloride | product | Feb 2031 |
| 8956649 | QUILLIVANT XRmethylphenidate hydrochloride | product | Feb 2031 |
| 9040083 | QUILLIVANT XRmethylphenidate hydrochloride | product | Feb 2031 |
| 10857143 | QUILLICHEW ERmethylphenidate hydrochloride | product | Aug 2033 |
| 11103494 | QUILLICHEW ERmethylphenidate hydrochloride | product | Aug 2033 |
| 11103495 | QUILLICHEW ERmethylphenidate hydrochloride | product | Aug 2033 |
| 11633389 | QUILLICHEW ERmethylphenidate hydrochloride | product | Aug 2033 |
| 8999386 | QUILLICHEW ERmethylphenidate hydrochloride | product | Aug 2033 |
| 9295642 | QUILLICHEW ERmethylphenidate hydrochloride | product | Aug 2033 |
| 9545399 | QUILLICHEW ERmethylphenidate hydrochloride | product | Aug 2033 |
| 9844544 | QUILLICHEW ERmethylphenidate hydrochloride | product | Aug 2033 |
Catalogue
Marketed products
13| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| DYANAVEL XR | amphetamine | tablet, extended release, oral | 24478-106NDA |
| DYANAVEL XR | amphetamine | tablet, extended release, oral | 24478-108NDA |
| DYANAVEL XR | amphetamine | tablet, extended release, oral | 24478-109NDA |
| DYANAVEL XR | amphetamine | tablet, extended release, oral | 24478-110NDA |
| Dyanavel XR | amphetamine | suspension, extended release, oral | 24478-102NDA |
| ONYDA XR | Clonidine hydrochloride | suspension, extended release, oral | 24478-148NDA |
| QuilliChew ER | methylphenidate hydrochloride | tablet, chewable, extended release, oral | 24478-074NDA |
| QuilliChew ER | methylphenidate hydrochloride | tablet, chewable, extended release, oral | 24478-075NDA |
| QuilliChew ER | methylphenidate hydrochloride | tablet, chewable, extended release, oral | 24478-076NDA |
| Quillivant XR | methylphenidate hydrochloride | suspension, extended release, oral | 24478-321NDA |
| Quillivant XR | methylphenidate hydrochloride | suspension, extended release, oral | 24478-322NDA |
| Quillivant XR | methylphenidate hydrochloride | suspension, extended release, oral | 24478-323NDA |
| Quillivant XR | methylphenidate hydrochloride | suspension, extended release, oral | 24478-324NDA |
Compare
Other companies listing methylphenidate hydrochloride
- Novartis Pharmaceuticals Corporation20 sites · 210 NDC
- Sandoz Industrial Products S.A5 sites · 441 NDC
- SpecGx LLC5 sites · 237 NDC
- Actavis LLC1 site · 309 NDC
- Lannett Company, LLC1 site · 190 NDC
- Societal CDMO Gainesville, LLC1 site · 55 NDC
- Vertical Pharmaceuticals, LLC0 sites · 15 NDC
- Aytu Therapeutics, LLC0 sites · 11 NDC
Enquiry
Common questions
- Is NextWave Pharmaceuticals, Inc FDA approved?
- NextWave Pharmaceuticals, Inc holds no registered establishment of its own; 13 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does NextWave Pharmaceuticals, Inc make?
- 13 products are listed under NextWave Pharmaceuticals, Inc in the openFDA NDC Directory, most often as suspension, extended release; tablet, extended release; tablet, chewable, extended release. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.